Background The lower airway microbiota in patients with chronic obstructive pulmonary disease (COPD) are likely altered compared with the microbiota in healthy individuals. Information on how the ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.